HK1099016A1 - Novel compounds as opioid receptor modulators - Google Patents

Novel compounds as opioid receptor modulators

Info

Publication number
HK1099016A1
HK1099016A1 HK07105593.3A HK07105593A HK1099016A1 HK 1099016 A1 HK1099016 A1 HK 1099016A1 HK 07105593 A HK07105593 A HK 07105593A HK 1099016 A1 HK1099016 A1 HK 1099016A1
Authority
HK
Hong Kong
Prior art keywords
opioid receptor
receptor modulators
novel compounds
synthesis
directed
Prior art date
Application number
HK07105593.3A
Other languages
English (en)
Inventor
Henry J Breslin
Chaozhong Cai
Wei He
Robert W Kavash
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34962827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1099016(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HK1099016A1 publication Critical patent/HK1099016A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Amplitude Modulation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Eye Examination Apparatus (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Amplifiers (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HK07105593.3A 2004-03-15 2007-05-28 Novel compounds as opioid receptor modulators HK1099016A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55334204P 2004-03-15 2004-03-15
PCT/US2005/008339 WO2005090315A1 (en) 2004-03-15 2005-03-14 Novel compounds as opioid receptor modulators

Publications (1)

Publication Number Publication Date
HK1099016A1 true HK1099016A1 (en) 2007-08-03

Family

ID=34962827

Family Applications (4)

Application Number Title Priority Date Filing Date
HK07105593.3A HK1099016A1 (en) 2004-03-15 2007-05-28 Novel compounds as opioid receptor modulators
HK07111210.4A HK1105967A1 (en) 2004-03-15 2007-10-17 Novel compounds as opioid receptor modulators
HK11109830.2A HK1155726A1 (en) 2004-03-15 2011-09-19 Opioid receptor modulators
HK13111031.3A HK1184432A1 (en) 2004-03-15 2013-09-27 Process for preparing intermediates of compounds useful as opioid receptor modulators

Family Applications After (3)

Application Number Title Priority Date Filing Date
HK07111210.4A HK1105967A1 (en) 2004-03-15 2007-10-17 Novel compounds as opioid receptor modulators
HK11109830.2A HK1155726A1 (en) 2004-03-15 2011-09-19 Opioid receptor modulators
HK13111031.3A HK1184432A1 (en) 2004-03-15 2013-09-27 Process for preparing intermediates of compounds useful as opioid receptor modulators

Country Status (36)

Country Link
US (8) US7741356B2 (pt)
EP (5) EP3112352B1 (pt)
JP (1) JP4778954B2 (pt)
KR (1) KR101166342B1 (pt)
CN (2) CN102786476B (pt)
AR (2) AR048269A1 (pt)
AT (1) ATE516274T1 (pt)
AU (1) AU2005224091B2 (pt)
BR (1) BRPI0508820B8 (pt)
CA (1) CA2560047C (pt)
CR (1) CR8655A (pt)
CY (3) CY1111927T1 (pt)
DK (5) DK3112352T3 (pt)
EC (1) ECSP066856A (pt)
ES (5) ES2533176T3 (pt)
HK (4) HK1099016A1 (pt)
HR (4) HRP20110694T1 (pt)
HU (2) HUE029852T2 (pt)
IL (3) IL178040A (pt)
LT (2) LT2653465T (pt)
LU (1) LUC00007I2 (pt)
ME (3) ME02540B (pt)
MX (1) MXPA06010642A (pt)
MY (1) MY146972A (pt)
NL (1) NL300865I2 (pt)
NO (3) NO338203B1 (pt)
NZ (1) NZ549842A (pt)
PH (1) PH12012501640A1 (pt)
PL (4) PL2298744T3 (pt)
PT (4) PT2573068E (pt)
RS (4) RS51995B (pt)
SI (4) SI2653465T1 (pt)
TW (1) TWI361069B (pt)
UA (1) UA86053C2 (pt)
WO (1) WO2005090315A1 (pt)
ZA (1) ZA200608587B (pt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
KR101166342B1 (ko) 2004-03-15 2012-07-18 얀센 파마슈티카 엔.브이. 아편계 약물 수용체 조절자로서의 신규의 화합물
NZ551288A (en) 2004-05-14 2010-10-29 Janssen Pharmaceutica Nv Carboxamido opioid compounds that are derivatives of tramadol
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
NZ590570A (en) * 2005-03-14 2012-06-29 Janssen Pharmaceutica Nv Process for the preparation of opioid modulators
AU2006325754B2 (en) * 2005-12-14 2012-04-12 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors
UA96283C2 (uk) * 2005-12-23 2011-10-25 Зіланд Фарма А/С Модифіковані міметики лізину
MX2008012991A (es) 2006-04-07 2008-10-17 Procter & Gamble Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos.
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US20080188545A1 (en) * 2006-12-21 2008-08-07 Alimardanov Asaf R Synthesis of pyrrolidine compounds
CA2695126C (en) * 2007-07-09 2018-10-30 Janssen Pharmaceutica, N.V. Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
JP5889529B2 (ja) 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
TWI468375B (zh) 2008-10-27 2015-01-11 Janssen Pharmaceutica Nv 製備經保護之ｌ－丙胺酸衍生物之方法
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
JP5198220B2 (ja) * 2008-11-13 2013-05-15 東ソ−・エフテック株式会社 アミノ酸誘導体の製造方法
RU2519123C2 (ru) 2009-07-06 2014-06-10 Аэрпио Терапьютикс Инк. Соединения, композиции и способы предупреждения метастазов раковых клеток
WO2012155199A1 (en) 2011-05-16 2012-11-22 Bionomics Limited Amine derivatives as potassium channel blockers
EP2524912A1 (en) 2011-05-16 2012-11-21 Bionomics Limited Amine derivatives
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
US9447079B2 (en) * 2013-03-14 2016-09-20 Epizyme, Inc. PRMT1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
SG11201506972PA (en) 2013-03-14 2015-10-29 Epizyme Inc Arginine methyltransferase inhibitors and uses thereof
US9675587B2 (en) * 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
US10702498B2 (en) 2015-07-09 2020-07-07 The Regents Of The University Of California MU opioid receptor modulators
WO2017015606A1 (en) * 2015-07-23 2017-01-26 Teva Pharmaceuticals International Gmbh Solid state forms of eluxadoline
JPWO2017043626A1 (ja) * 2015-09-11 2018-06-21 株式会社カネカ 光学活性４−カルバモイル−２，６−ジメチルフェニルアラニン誘導体の製造法
KR20180054677A (ko) 2015-09-23 2018-05-24 에르피오 세러퓨틱스 인코포레이티드 Tie-2의 활성화제로 안내압을 치료하는 방법
CN105250232B (zh) * 2015-09-29 2018-08-14 江苏汇智知识产权服务有限公司 一种伊卢多啉肠溶片及其制备方法
WO2017114446A1 (zh) * 2015-12-31 2017-07-06 苏州晶云药物科技有限公司 艾沙度林的新晶型及其制备方法
CN107129444B (zh) * 2016-02-29 2018-08-31 尚科生物医药（上海）有限公司 (s)-2-叔丁氧羰基氨基-3-(4-氨甲酰基-2,6-二甲基苯基)丙酸制备方法
EP3272741A1 (en) 2016-07-21 2018-01-24 Euticals S.P.A. New stable solvate crystalline forms of eluxadoline
CN105777584B (zh) * 2016-03-28 2018-01-02 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
CN105693554B (zh) * 2016-04-06 2017-08-08 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
US20190177281A1 (en) * 2016-05-03 2019-06-13 Sromovasam THIRUMALAI RAJAN Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl] [(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino] methyl-2-methoxybenzoic acid and its polymorphs thereof
MA45184A (fr) * 2016-05-30 2019-04-10 Sun Pharmaceutical Ind Ltd Procédé de préparation de l'éluxadoline .
US10822308B2 (en) * 2016-06-23 2020-11-03 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018020450A2 (en) 2016-07-28 2018-02-01 Lupin Limited Process for the preparation of eluxadoline
CZ2016548A3 (cs) 2016-09-07 2018-03-14 Zentiva, K.S. Pevné formy eluxadolinu
WO2018047131A1 (en) * 2016-09-09 2018-03-15 Sun Pharmaceutical Industries Limited Amorphous eluxadoline
EP3515434A4 (en) * 2016-09-20 2020-02-26 Sun Pharmaceutical Industries Limited METHOD FOR PRODUCING ELUXADOLIN
US10738013B2 (en) 2017-01-27 2020-08-11 Quimica Sintetica, S.A. Eluxadoline crystalline forms and processes for their preparation
WO2018138272A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline form and process for the preparation thereof
CN110709096B (zh) 2017-05-05 2023-10-31 泽兰德制药公司 细胞间隙连接通讯调节剂及其在糖尿病性眼病治疗中的应用
WO2019008604A1 (en) 2017-07-07 2019-01-10 Cipla Limited NEW FORMS OF MU-OPIOID RECEPTOR AGONIST
WO2019144805A1 (zh) * 2018-01-25 2019-08-01 四川科伦博泰生物医药股份有限公司 取代的苯乙胺化合物及其制备方法和用途
WO2019197274A1 (en) 2018-04-09 2019-10-17 Quimica Sintetica, S. A. Process for the preparation of opioid modulators
WO2020039333A1 (en) 2018-08-20 2020-02-27 Allergan Holdings Unlimited Company Polymorphs of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
CN113164597A (zh) 2018-09-24 2021-07-23 爱尔皮奥制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
ES2867895T3 (es) * 2018-11-30 2021-10-21 Phytobiotics Futterzusatzstoffe Gmbh Sistema para el análisis de imágenes de excrementos de animales
CN111377832A (zh) * 2018-12-27 2020-07-07 江苏联昇化学有限公司 一种伊卢多啉中间体制备的新方法
AU2020264969A1 (en) 2019-04-29 2021-12-09 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
WO2021198780A1 (en) 2020-03-30 2021-10-07 Allergan Holdings Unlimited Company Forms of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
EP4188923A1 (en) * 2020-07-28 2023-06-07 Jazz Pharmaceuticals Ireland Limited Chiral synthesis of fused bicyclic raf inhibitors
US11850319B2 (en) 2020-09-29 2023-12-26 Abl Ip Holding Llc Techniques for directing ultraviolet energy towards a moving surface
US12115269B2 (en) 2020-09-29 2024-10-15 ABL Holding Holding LLC Techniques for directing ultraviolet energy towards a moving surface
CN114163348A (zh) * 2020-11-27 2022-03-11 成都泰蓉生物科技有限公司 一种氨酰基取代的l-苯丙氨酸的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD142804A3 (de) * 1977-11-07 1980-07-16 Wagner Guenter Verfahren zur herstellung von na-alkyl-bzw.na-aryl-sulfonylierten omega-amidinophenyl-alpha-aminoalkylcarbonsaeureamiden
US4879398A (en) * 1987-12-31 1989-11-07 Monsanto Company Process for producing 2,6-disubstituted tyrosine
SE9402880D0 (sv) 1994-08-30 1994-08-30 Astra Ab New peptide derivatives
ID18218A (id) 1995-01-27 1998-03-19 Novo Nordisk As Senyawa dengan sifat-sifat pelepas hormon pertumbuhan
US5565568A (en) 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists
CA2217006C (en) 1995-04-13 2001-05-22 Hoechst Marion Roussel, Inc. Novel substituted piperazine derivatives having tachykinin receptor antagonists activity
WO1997006803A1 (en) 1995-08-21 1997-02-27 Eli Lilly And Company 2-acylaminopropanamides as growth hormone secretagogues
WO1997019908A1 (en) 1995-11-29 1997-06-05 Nihon Nohyaku Co., Ltd. Phenylalanine derivatives, optically active substances, salts or coordination compounds thereof, and their use as fungicides
US5792760A (en) 1997-04-23 1998-08-11 Eli Lilly And Company Bisindoles as tachykinin receptor antagonists
IT1304898B1 (it) 1998-09-08 2001-04-05 Menarini Ricerche Spa Prodotti con caratteristiche basiche aventi attivita' antagonista sulrecettore nk-1 e loro impiego in preparazioni farmaceutiche
DK1055665T3 (da) * 1999-05-28 2004-03-01 Pfizer Prod Inc 3-(3-hydroxyphenyl)-3-aminopropionamidderivater
FR2796643B1 (fr) 1999-07-22 2005-04-29 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
GB0021419D0 (en) 2000-08-31 2000-10-18 Oxford Glycosciences Uk Ltd Compounds
US20020072017A1 (en) * 2000-10-19 2002-06-13 Hudnall Phillip Montgomery Stabilized p-phenylenediamine-type photographic color developers in free base form
JP2004512365A (ja) 2000-10-30 2004-04-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ トリペプチジルペプチダーゼ阻害剤
EA006507B1 (ru) * 2001-10-15 2005-12-29 Янссен Фармацевтика Н.В. Новые замещенные 4-фенил-4-[1h-имидазол-2-ил] пиперидиновые производные и их применение в качестве селективных непептидных агонистов дельта-опиоидов
US7041681B2 (en) * 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
KR101166342B1 (ko) 2004-03-15 2012-07-18 얀센 파마슈티카 엔.브이. 아편계 약물 수용체 조절자로서의 신규의 화합물
WO2005111028A1 (en) * 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
NZ590570A (en) * 2005-03-14 2012-06-29 Janssen Pharmaceutica Nv Process for the preparation of opioid modulators

Also Published As

Publication number Publication date
RS54199B1 (en) 2015-12-31
US10213415B2 (en) 2019-02-26
US20050203143A1 (en) 2005-09-15
RS55122B1 (sr) 2016-12-30
LT2653465T (lt) 2016-09-12
HRP20150305T1 (hr) 2015-04-24
EP2653465B1 (en) 2016-07-13
EP3112352A1 (en) 2017-01-04
LUC00007I1 (pt) 2017-03-03
US7741356B2 (en) 2010-06-22
CY2017008I1 (el) 2017-11-14
ATE516274T1 (de) 2011-07-15
JP2007529527A (ja) 2007-10-25
DK2298744T3 (da) 2013-09-02
EP2298744A3 (en) 2011-08-10
IL178040A (en) 2013-12-31
CN1950342A (zh) 2007-04-18
HUS1700010I1 (hu) 2017-03-28
RS52933B (en) 2014-02-28
PT2573068E (pt) 2015-04-27
DK2653465T3 (da) 2016-08-22
HRP20130800T1 (en) 2013-09-30
DK1725537T3 (da) 2011-10-31
NL300865I2 (nl) 2020-08-17
HK1184432A1 (en) 2014-01-24
NZ549842A (en) 2010-10-29
BRPI0508820B1 (pt) 2018-04-10
AU2005224091B2 (en) 2012-02-02
CA2560047A1 (en) 2005-09-29
CY1118096T1 (el) 2017-06-28
UA86053C2 (ru) 2009-03-25
SI2298744T1 (sl) 2013-10-30
PL2653465T3 (pl) 2017-01-31
AR048269A1 (es) 2006-04-12
US20140256779A1 (en) 2014-09-11
PL1725537T3 (pl) 2011-12-30
ME01601B (me) 2014-09-20
US20130090478A1 (en) 2013-04-11
US8772325B2 (en) 2014-07-08
ECSP066856A (es) 2006-11-24
SI2573068T1 (sl) 2015-03-31
ES2428008T3 (es) 2013-11-05
IL224908A (en) 2015-07-30
US20100324051A1 (en) 2010-12-23
ZA200608587B (en) 2008-06-25
HRP20161331T1 (hr) 2016-12-30
MXPA06010642A (es) 2007-03-26
SI1725537T1 (sl) 2011-11-30
US20160030393A1 (en) 2016-02-04
US8344011B2 (en) 2013-01-01
HK1155726A1 (en) 2012-05-25
MY146972A (en) 2012-10-15
CA2560047C (en) 2013-12-24
NO20160916A1 (no) 2006-12-14
EP1725537B1 (en) 2011-07-13
CN1950342B (zh) 2012-09-26
DK3112352T3 (en) 2019-01-28
ES2533176T3 (es) 2015-04-08
WO2005090315A1 (en) 2005-09-29
PT2653465T (pt) 2016-09-22
ME02540B (me) 2017-02-20
EP2298744B1 (en) 2013-06-26
NO2017007I1 (no) 2017-02-23
TWI361069B (en) 2012-04-01
US20080096888A1 (en) 2008-04-24
PH12012501640B1 (en) 2015-10-05
LUC00007I2 (pt) 2017-05-02
EP1725537A1 (en) 2006-11-29
CN102786476B (zh) 2017-01-18
BRPI0508820A (pt) 2007-08-07
IL229444A0 (en) 2013-12-31
AR095848A2 (es) 2015-11-18
US8609709B2 (en) 2013-12-17
PT2298744E (pt) 2013-09-12
TW200539876A (en) 2005-12-16
EP2573068A1 (en) 2013-03-27
EP2573068B1 (en) 2014-12-31
CN102786476A (zh) 2012-11-21
CY1111927T1 (el) 2015-11-04
RS51995B (en) 2012-04-30
ES2367576T3 (es) 2011-11-04
HK1105967A1 (en) 2008-02-29
PT1725537E (pt) 2011-09-08
ES2705077T3 (es) 2019-03-21
CR8655A (es) 2008-09-09
PL2573068T3 (pl) 2015-06-30
US7786158B2 (en) 2010-08-31
JP4778954B2 (ja) 2011-09-21
KR101166342B1 (ko) 2012-07-18
US9205076B2 (en) 2015-12-08
NO338203B1 (no) 2016-08-08
LTC1725537I2 (lt) 2018-02-26
CY2017008I2 (el) 2017-11-14
IL229444A (en) 2017-03-30
NO2017007I2 (no) 2017-02-23
KR20060131983A (ko) 2006-12-20
EP2298744A2 (en) 2011-03-23
US9700542B2 (en) 2017-07-11
DK2573068T3 (en) 2015-02-16
AU2005224091A1 (en) 2005-09-29
HRP20110694T1 (hr) 2011-12-31
EP2573068B9 (en) 2015-08-26
US20140039024A1 (en) 2014-02-06
LTPA2017005I1 (lt) 2017-03-27
NL300865I1 (nl) 2017-03-14
PL2298744T3 (pl) 2013-11-29
US20180325870A1 (en) 2018-11-15
ES2596434T3 (es) 2017-01-09
EP3112352B1 (en) 2018-11-21
SI2653465T1 (sl) 2016-10-28
ME02221B (me) 2016-02-20
BRPI0508820B8 (pt) 2022-11-29
IL178040A0 (en) 2006-12-31
PH12012501640A1 (en) 2015-10-05
HUE029852T2 (en) 2017-04-28
EP2653465A1 (en) 2013-10-23
NO20064660L (no) 2006-12-14

Similar Documents

Publication Publication Date Title
HK1105967A1 (en) Novel compounds as opioid receptor modulators
HU0400405D0 (en) Novel compounds
NO20084783L (no) Syntese av acylaminoalkenylenamider nyttige som substans P antagonister
SE0303180D0 (sv) Novel compounds
HK1159064A1 (en) Processes for the preparation of aminosulfone compounds
SE0201635D0 (sv) Novel compounds
TW200503724A (en) Novel pharmaceuticals
MX2009000475A (es) Nuevos compuestos de espiropiperidina triciclicos, su sintesis y sus usos como moduladores de la actividad de los receptores de quimioquinas.
MY136959A (en) Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
MX2009005461A (es) N-oxidos de analogos de 4,5-epoxi-morfinano.
EA200701588A1 (ru) Способы получения замещённых фенилпиразолмочевин
HK1125358A1 (en) Substituted cyclohexylmethyl derivatives
HK1080088A1 (zh) 製備c-7取代的5-雄甾烯的方法
RS20080119A (en) Carboxamide derivatives as muscarinic receptor antagonists
MX2007007446A (es) Procesos para la produccion de 4-aminoquinazolinas.
TW200714587A (en) Biphenyl compounds useful as muscarinic receptor antagonists
MX2007007720A (es) Derivados de pirrolidinio como receptores m3 muscarinicos.
UA101482C2 (ru) Способ получения 2'-дезокси-5-азацитидина (децитабина)
WO2007082262A3 (en) Novel compounds
TW200738713A (en) Diazepinoquinolines, synthesis thereof, and intermediates thereto
SI1723140T1 (sl) Postopek za pripravo inhibitorjev triptaze
TW200640870A (en) Novel compounds
NO20076161L (no) Fremgangsmater for fremstilling av 4-bifenylazetidin-2-oner
TW200616624A (en) 2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230314